设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:中国医师协会
总编辑:
杨秋

编辑部主任:吴翔宇

邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

过刊目录

2024 年第 5 期 第 0 卷

蒙药清血八味散联合苯磺酸氨氯地平对原发性高血压患者血液流变学的影响

Effect of Mongolian medicine Qingxue Bawei powder combined with amlodipine besylate on hemorheology in patients with essential hypertension

作者:那仁满都拉1 包晓庆2 杨敖民2

英文作者:Narenmandula1 Bao Xiaoqing2 Yang Aomin2

单位:1内蒙古自治区人民医院蒙医科,呼和浩特010017;2内蒙古医科大学研究生学院,呼和浩特010010

英文单位:1Department of Mongolian Medicine People′s Hospital of Inner Mongolia Autonomous Region Hohhot 010017 China; 2Graduate School of Inner Mongolia Medical University Hohhot 010010 China

关键词:原发性高血压;蒙药清血八味散;血液流变学;临床研究

英文关键词:Essentialhypertension;MongolianmedicineQingxueBaweipowder;Hemorheology;Clinicalstudy

  • 摘要:
  • 目的  研究蒙药清血八味散联合苯磺酸氨氯地平对原发性高血压患者血液流变学及相关指标的影响。方法  选取2021年3月至2023年2月于内蒙古自治区人民医院接受治疗的原发性高血压患者,根据随机数字表法分为观察组(31例)和对照组(29例)。对照组予苯磺酸氨氯地平片口服治疗,观察组在对照组基础上联合清血八味散口服治疗,2组疗程均为30 d。观察2组患者治疗前后血液流变学、血脂、同型半胱氨酸(Hcy)、高敏C反应蛋白(hs-CRP)、血压水平以及安全性指标的变化情况。结果  治疗后,观察组全血高切相对指数、全血低切相对指数、血浆黏度、红细胞聚集指数均较治疗前有改善,且全血高切相对指数、全血低切相对指数改善幅度均大于对照组[3.04(0.89,5.51)比0.69(0.13,1.93)、5.22(2.83,8.97)比2.64(1.34,5.19)](均P<0.05)。治疗后,观察组高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇、甘油三酯均较治疗前有所改善,且HDL-C、LDL-C、甘油三酯改善幅度均大于对照组(均P<0.05)。治疗后,观察组Hcy、hs-CRP、收缩压、舒张压水平均较治疗前有改善,且Hcy、hs-CRP、舒张压改善幅度均大于对照组(均P<0.05)。治疗前后,2组血常规及肝肾功能各项指标均在正常范围之内,2组不良反应发生率比较差异无统计学意义(P>0.05)。结论  蒙药清血八味散联合苯磺酸氨氯地平对原发性高血压患者血液流变学以及相关指标具有一定的改善作用,且改善作用明显优于苯磺酸氨氯地平单药。

  • Objective  To investigate the effect of Mongolian medicine Qingxue Bawei powder combined with amlodipine besylate on hemorheology and related indexes in patients with essential hypertension. Methods  Patients with essential hypertension who were treated in People′s Hospital of Inner Mongolia Autonomous Region from March 2021 to February 2023 were selected. According to the random number table method, they were divided into the observation group (31 cases) and the control group (29 cases).The control group was treated with amlodipine besylate tablets, and the observation group was treated with Qingxue Bawei powder on the basis of the control group. Both groups were treated for 30 d.The changes of hemorheology, blood lipid, homocysteine (Hcy), high-sensitive C-reaction protein (hs-CRP), blood pressure level and safety indexes were observed before and after treatment. Results  After treatment, whole blood high-resection relative index, whole blood low-resection relative index, plasma viscosity and erythrocyte aggregation index in the observation group were improved compared with those before treatment, and the improvement of whole blood high-resection relative index and whole blood low-resection relative index were greater than those in the control group [3.04(0.89,5.51) vs 0.69(0.13,1.93), 5.22(2.83,8.97) vs 2.64(1.34,5.19)](all P<0.05). After treatment, the levels of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol and triacylglycerol in the observation group were all improved compared with those before treatment, and the levels of HDL-C, LDL-C and triacylglycerol were improved more than those in the control group(all P<0.05). After treatment, the levels of Hcy, hs-CRP, systolic blood pressure and diastolic blood pressure in the observation group were all improved, and the improvement of Hcy, hs-CRP and diastolic blood pressure were greater than those in the control group(all P<0.05). Before and after treatment, the blood routine and liver and kidney function indexes of the two groups were within the normal range, and there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion  Mongolian medicine Qingxue Bawei powder combined with amlodipine besylate has a certain improvement effect on hemorheology and related indicators in patients with essential hypertension, and the improvement effect is significantly better than amlodipine besylate alone.

copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址:www.chinamedicinej.com 京ICP备2020043099号-3

当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭